Three "field effect" epigenetic biomarkers were found to be more prevalent in histologically benign biopsy cores from prostate cancer patients diagnosed with Gleason score 7 prostate cancer than in those with low-volume Gleason 6 disease, researchers reported at the Genitourinary Cancers Symposium in Orlando, FL.
Patients with high-risk prostate cancer who received 18 months of hormone therapy lived as long as patients treated for 36 months, Canadian researchers report.
A large study presented at the Genitourinary Cancers Symposium in Orlando, FL has confirmed that prostate cancer detection rates are enhanced when 10 to 12 specimens are obtained during biopsy.
The FDA has granted priority review to the new drug application filed for radium-223 dichloride, an investigational compound under review for the treatment of patients with castration-resistant prostate cancer who have bone metastases.
Nearly a quarter of family physicians order PSA tests without discussing the test with patients, according to a recent study.
New research shows that men with a high risk of bone fracture who are undergoing long-term androgen deprivation therapy (ADT) for prostate cancer have a higher fracture incidence following treatment completion.
More than 3% of prostate biopsies are subject to medical errors or contamination, a recent study found.
In May 2012, the United States Preventive Services Task Force recommended against PSA testing in all men based upon a flawed analysis that overestimated the harms and underestimated the benefits of testing.
This special installment of "Hands On" is presented in a point-counterpoint format, with two leading experts discussing open versus. robot-assisted radical prostatectomy.